Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study-Reference-Cited by-同舟云学术

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study

Published:2010-12 Issue:3 Volume:119 Page:444-450
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Hurteau Jean A.,Brady Mark F.,Darcy Kathleen M.,McGuire William P.,Edmonds Pamela,Pearl Michael L.,Ivanov Iouri,Tewari Krishnansu S.,Mannel Robert S.,Zanotti Kristine,Benbrook Doris M.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference34 articles.

1. Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up;Tuxen;Scand J Clin Lab Invest,2002

2. A randomized trial in ovarian cancer of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OVO5/EORTC 55955 trials);Rustin;J Clin Oncol,2009

3. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer;Ghamande;Gynecol Oncol,2008

4. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients;Hatch;Cancer,1991

5. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report;Markman;Gynecol Oncol,1996

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted therapy and molecular genetics;DiSaia and Creasman Clinical Gynecologic Oncology;2023

2. Recurrent High Grade Serous Ovarian Cancer Management;Ovarian Cancer;2022-08-06

3. Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR);Gynecologic Oncology;2022-01

4. Highly Expressed Progesterone Receptor B Isoform Increases Platinum Sensitivity and Survival of Ovarian High-Grade Serous Carcinoma;Cancers;2021-11-08

5. The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value;Gynecologic Oncology;2021-05